Загрузка...
Immune-mediated Adverse Effects of Anti-CTLA-4 Antibody Therapy in Metastatic Melanoma
Ipilimumab, an antibody that blocks cytotoxic T lymphocyte-associated antigen-4 (CTLA-4; CD152), was approved by the Food and Drug Administration (FDA) in 2011 for the treatment of unresectable stage III or IV malignant melanoma. Although the addition of this particular immunotherapy has broadened t...
Сохранить в:
| Опубликовано в: : | Transl Res |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4609598/ https://ncbi.nlm.nih.gov/pubmed/26118951 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trsl.2015.06.005 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|